<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042766</url>
  </required_header>
  <id_info>
    <org_study_id>094-2019</org_study_id>
    <nct_id>NCT04042766</nct_id>
  </id_info>
  <brief_title>Laser Vaginal Treatment for GSM</brief_title>
  <official_title>Laser Vaginal Treatment for GSM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovation Fund of the Alternative Funding Plan from the Academic Health Sciences Centres of Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genitourinary Syndrome of Menopause (GSM) due to low estrogen levels affects about half of
      post-menopausal women and may have a dramatic impact on women's quality of life. Women
      complain of vaginal dryness, itching, discomfort, malodour, painful intercourse and may have
      urinary urgency, irritation, bladder/urethral pain and recurring bladder infections.
      First-line therapies include vaginal moisturizers, lubricants and estrogen (either oral or
      with vaginal cream/tablets). While these therapies are effective, the ongoing costs and the
      resistance to the indefinite use of vaginal creams/inserts is a challenge to the continued
      use of these therapies. Recently, an innovative laser therapy has been used to treat women
      with GSM. A randomized controlled trial (RCT) to study how effective the laser is to treat
      women with GSM is planned.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>subjective measure of change in: the patient's most bothersome symptom</measure>
    <time_frame>Baseline and 3 months after treatment start</time_frame>
    <description>The most bothersome symptom of GSM (vaginal dryness, discomfort, itching, dyspareunia, urinary urgency, dysuria) will be identified and its severity rated on a standardized 4-point scale: 0=none, 1=mild, 2=moderate, 3=severe</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Menopausal Urethral Atrophy</condition>
  <condition>Vulvar Atrophy</condition>
  <arm_group>
    <arm_group_label>laser treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laser vaginal treatment</intervention_name>
    <description>Er:YAG laser</description>
    <arm_group_label>laser treatment</arm_group_label>
    <arm_group_label>sham treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females aged 45-70 years;

          2. 2 or more years since last natural menstrual period, or surgical menopause (bilateral
             oophorectomy);

          3. at least 1 vaginal symptom reported from the following list, experienced for the past
             30 days which is moderate or severe at least once a week: dryness | itching |
             irritation | soreness/pain | dyspareunia;

          4. no concurrent or new planned treatment for GSM during the treatment period and the 3
             months following it;

          5. vaginal anatomy allows for laser therapy; 6) willing and able to comply with the study
             protocol.

        Exclusion Criteria:

          1. Patient is pregnant/lactating

          2. unexplained abnormal genital bleeding

          3. current acute vaginal/ bladder infection

          4. antibiotic use the past 30 days;

          5. women under age 55 with endometrial ablation/ hysterectomy/ at least one ovary;

          6. concurrent use of any other new GSM treatment

          7. pelvic surgery &lt;3 months

          8. current treatment for chronic pelvic pain
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanne Lawrence, BSc</last_name>
    <phone>4164806100</phone>
    <phone_ext>2309</phone_ext>
    <email>joanne.lawrence@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre, University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Lawrence, BSc</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

